Clinical trials: Carcinoma of Prostate (Disorder)
Prostate Cancer
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
This is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of CASODEX.
- Trial name
- NCT00846976
- Testing
- Bicalutamide
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Breast Cancer, Non-small Cell Lung Cancer
Study to Evaluate the Safety of Nanoxel M Inj.
Study to evaluate the safety of Nanoxel M inj. administration in patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Ovarian Cancer
- Trial name
- NCT04066335
- Where
- South Korea
- Volunteers
- 1,498 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Prostatic Neoplasms
Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer
The purpose of this study is to evaluate the clinical benefit of the co-administration of propranolol and etodolac (VT-122 therapy) in patients with clinically progressive prostate cancer.
- Trial name
- NCT01857817
- Testing
- VT-122
- Where
- 16 sites in United States
- Volunteers
- 35 people
- Sponsor
- Vicus Therapeutics
Urinary Incontinence, Prostate Cancer
Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
The purpose of this study is to determine the impact of an absorbable urethrovesical sling on the post-operative return of urinary continence after robot-assisted radical prostatectomy.
- Trial name
- NCT00937833
- Testing
- Prostatectomy, Surgisis Male Sling
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Cook Group Incorporated
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic…
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
- Trial name
- NCT05519449
- Testing
- JANX007, Darolutamide
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 272 people
- Sponsor
- Janux Therapeutics
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle.
- Conditions
- Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
- Trial name
- NCT04729114
- Testing
- PRL-02 injection, prednisone, dexamethasone
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)
The purpose of this study is to investigate the effects of MK0822 in prolonging the time to first bone metastasis in men with castration-resistant prostate cancer.
- Trial name
- NCT00691899
- Testing
- odanacatib
- Sponsor
- Merck Sharp & Dohme LLC
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not…
- Trial name
- NCT03834493
- Testing
- Pembrolizumab, Enzalutamide
- Where
- 259 sites in United States, Argentina and 26 more
- Volunteers
- 1,244 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking.
- Trial name
- NCT05701007
- Testing
- abiraterone, enzalutamide, docetaxel
- Where
- Finland
- Volunteers
- 1,083 people
- Sponsor
- Pfizer
Metastatic Prostate Cancer
Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer
The proposed phase 1 clinical trial will investigate the safety and tolerability of 177Lu-CYT-500 in patients with metastatic prostate cancer and determine the optimal antibody mass and dose of 177Lu to be used for further study.
- Trial name
- CYT-500 (NCT00441571)
- Testing
- 177Lu-CYT-500
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cytogen Corporation
Prostate Cancer
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
The objective of this study is to assess the effect Of zoledronic acid on circulating and bone marrow-residing prostate cancer cells in patients with clinically localized prostate cancer
- Trial name
- NCT00219271
- Testing
- Zoledronic acid
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.
- Trial name
- NCT06517719
- Testing
- lutetium (177Lu) vipivotide tetraxetan
- Where
- 38 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Prostate
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth.
- Trial name
- NCT00470834
- Testing
- dutasteride, bicalutamide
- Where
- 62 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).
- Trial name
- NCT01591122
- Testing
- Abiraterone acetate and prednisone
- Where
- 22 sites in China, Malaysia and 2 more
- Volunteers
- 313 people
- Sponsor
- Janssen Research & Development, LLC
Benign Prostatic Hyperplasia, Prostate Cancer
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
Dutasteride is used in the treatment of benign prostate enlargement (BPH).It inhibits conversion of testosterone (T) into the more potent dihydrotestosterone (DHT) to stop prostate (and possibly prostate cancer) growth.
- Trial name
- NCT00375765
- Testing
- Dutasteride
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer, Non-small Cell Lung Cancer
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Primary Objectives: To characterize the safety and tolerability of isatuximab in combination with REGN2810 in participants with metastatic, castration-resistant prostate cancer (mCRPC) who were naïve to anti-programmed cell…
- Trial name
- NCT03367819
- Testing
- Isatuximab SAR650984, Cemiplimab REGN2810
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Sanofi
Prostate Cancer
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
The purpose of this study is to determine a safe, effective, and tolerable dose of PRX302 for the treatment of low to intermediate risk prostate cancer.
- Trial name
- NCT03081481
- Testing
- PRX302
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 38 people
- Sponsor
- Sophiris Bio Corp
Neoplasms, Prostate
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
- Trial name
- NCT07332455
- Testing
- GSK5471713
- Where
- 20 sites in United States, Australia and 6 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Prostate Cancer
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
This was a Phase II, multi-center, open label, single dose study in patients with tumor types known to overexpress Gastrin-Releasing Peptide Receptor (GRPR), including breast, prostate, colorectal, Non-Small Cell Lung Cancer…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, Non Small Cell Lung Cancer
- Trial name
- NeoFIND (NCT03724253)
- Testing
- [68Ga]-NeoBOMB1
- Where
- 3 sites in Austria, France
- Volunteers
- 19 people
- Sponsor
- Advanced Accelerator Applications
Prostate Cancer
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a…
- Trial name
- NCT00514072
- Testing
- BCG vaccine, prostate cancer vaccine ONY-P1
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Kael-GemVax Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.